Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.59 |
| ▸ | CA1 | P00915 | 6/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903377 | 1.00 | CA2 (0.59) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL2905078 | 0.92 | TSHR (0.52) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL3744882 | 0.92 | TSHR (0.52) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL3050377 | 0.92 | TSHR (0.52) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL3746359 | 0.87 | ITGB3 (0.47) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL2906079 | 0.87 | ITGB3 (0.47) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL2906080 | 0.87 | ITGB3 (0.47) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL3749426 | 0.87 | CA2 (0.53) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL3044049 | 0.87 | CA2 (0.53) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL2903708 | 0.86 | ITGB3 (0.46) | CA2CA1CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, NPBWR1 | CA2 2626/4885CA1 3486/4885CA12 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.